Publications

Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma

Meyers et al. (2024) 

Journal of Clinical Oncology


An EWS::FLI1 monoclonal antibody with multimodal utility and specificity for FLI1

Saravana Selvanathan, Jeffrey Toretsky (2023)

bioRxiv


Comprehensive profiling of mRNA splicing indicates that GC content signals altered cassette exon inclusion in Ewing sarcoma

Graham et al. (2022) 

NAR Cancer


Clofarabine induces ERK/MSK/CREB activation through inhibiting CD99 on Ewing sarcoma cells

Sevim et al. (2021)

PLoS One


 Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives

Zöllner et al. (2021) 

Ewing Sarcoma

Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279

Conn et al. (2020) 

Mol Med Rep

The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents 


Spriano et al. (2019) 

Clinical Cancer Research

EWS–FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex

Selvanathan et al. (2019) 

Nucleic Acids Res.